Clinical trials: Refractory Heart Failure
ARDS Related to Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV) 2, Acute Refractory Heart Failure Related to SARS-CoV 2
Extracorporeal Membrane Oxygenation (ECMO) and Coronavirus Disease (COVID) 19
The role of ECMO in the treatment of patients with severe COVID-19 (Acute Respiratory Distress Syndrome (ARDS) and/or acute refractory heart failure) is not yet known.
- Trial name
- ECMO-SARS (NCT04397588)
- Where
- 44 sites in France
- Volunteers
- 761 people
- Sponsor
- Rennes University Hospital
Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy
Optimizing Left Ventricular Lead To Improve Cardiac Output
The purpose of this study is to determine if optimal lead placement, guided by the largest improvement in aortic flow measured by Doppler will: 1. Improve the way the heart's left ventricle functions 2.
- Conditions
- Ischemic Congestive Cardiomyopathy, Dilated Cardiomyopathy, Congestive Heart Failure
- Trial name
- CARE/VOLCANO (NCT01399801)
- Testing
- Doppler flow measurement, standard implantation of the LV lead
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Ann Marie Chikowski
Heart Decompensation
Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart Failure
Open label study of levosimendan; planned comparison for effectiveness and safety to historic matched case controls from participating sites.
- Trial name
- NCT02973620
- Testing
- Levosimendan
- Sponsor
- Tenax Therapeutics, Inc.
Advanced Refractory Left Ventricular Heart Failure
MOMENTUM 3 Pivotal Cohort Extended Follow-up PAS
The study will be a prospective, multi-center, non-blinded, controlled study, intended to evaluate the extended use of the HM3 LVAS compared to the HMII LVAS in those patients that are ongoing at the 2-year follow-up in the…
- Trial name
- NCT03982979
- Testing
- HM3 LVAS
- Where
- United States
- Volunteers
- 295 people
- Sponsor
- Abbott Medical Devices